See more : Stratec SE (SBS.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Ocean Biomedical, Inc. (OCEA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ocean Biomedical, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Graphex Group Limited (GRFX) Income Statement Analysis – Financial Results
- Avolta AG (DUFN.SW) Income Statement Analysis – Financial Results
- WarpSpeed Taxi Inc. (WRPT) Income Statement Analysis – Financial Results
- L&F Acquisition Corp. (LNFA-UN) Income Statement Analysis – Financial Results
- CIMC Enric Holdings Limited (CIMEF) Income Statement Analysis – Financial Results
Ocean Biomedical, Inc. (OCEA)
About Ocean Biomedical, Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 33.93M | 49.00K | 35.00K |
| General & Administrative | 0.00 | 28.41M | 1.60M | 197.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.48M | 28.41M | 1.60M | 197.00K |
| Other Expenses | 0.00 | 1.00K | -1.00K | 0.00 |
| Operating Expenses | 2.48M | 62.35M | 1.65M | 232.00K |
| Cost & Expenses | 2.48M | 62.35M | 1.65M | 232.00K |
| Interest Income | 1.52M | 2.45K | 0.00 | 0.00 |
| Interest Expense | 691.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.52M | 236.56K | 206.30K | 171.86K |
| EBITDA | -957.74K | -564.11K | -1.65M | -232.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.48M | -62.35M | -1.65M | -232.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.52M | 61.78M | -1.00K | 0.00 |
| Income Before Tax | -958.43K | -62.34M | -1.65M | -232.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -236.56K | -206.30K | -171.86K |
| Net Income | 565.47K | -62.34M | -1.65M | -232.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -4.71 | -0.08 | -0.01 |
| EPS Diluted | -0.03 | -4.71 | -0.08 | -0.01 |
| Weighted Avg Shares Out | 36.50M | 13.23M | 20.20M | 20.20M |
| Weighted Avg Shares Out (Dil) | 36.50M | 13.23M | 20.20M | 20.20M |
Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics
Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwide
Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide
3 Growth Stocks To Make You The Millionaire Next Door: October Edition
Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund
Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million
Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca's Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.
Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.
Source: https://incomestatements.info
Category: Stock Reports